Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
Fulcrum Therapeutics, Inc.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
| Security Type | Security Class Title | Fee Calculation Rule | Amount Registered (1) | Proposed Maximum Offering Price Per Share | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | |||||||
| Equity | Common Stock, $0.001 par value per share | 457(c) and 457(h)(1) | 1,000,000 (2) | $8.68 (3) | $8,680,000 | $0.00014760 | $1,281.17 | |||||||
| Total Offering Amounts | $8,680,000 | $1,281.17 | ||||||||||||
| Total Fee Offsets | $0 | |||||||||||||
| Net Fee Due | $1,281.17 | |||||||||||||
| (1) | In accordance with Rule 416 under the Securities Act of 1933, as amended (the “Act”), this registration statement shall be deemed to cover any additional securities that may from time to time be offered or issued to prevent dilution resulting from stock splits, stock dividends or similar transactions. Pursuant to Rule 416(c) under the Act, this registration statement shall also cover an indeterminate amount of interests to be offered or sold pursuant to the employee benefit plan described herein. |
| (2) | Consists of 1,000,000 shares issuable under the registrant’s 2022 Inducement Stock Incentive Plan, as amended. |
| (3) | Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) and (h)(1) of the Act, and based on $8.68, the average of the high and low sale prices of the registrant’s common stock as reported on The Nasdaq Global Market on July 25, 2024. |
